Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance

• Published in: BMC genomics 2018-07, Vol.19 (1), p.513-513, Article 513
• Main Authors: Minchin, Rodney F, Butcher, Neville J
• Format: Article
• Language: English
• Subjects: Acetyltransferase; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Hormonal - therapeutic use; Arylamine N-acetyltransferase; Arylamine N-Acetyltransferase - genetics; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer therapies; Care and treatment; Cell growth; Cell proliferation; Cervix; Chemotherapy; Drug resistance; Drug Resistance, Neoplasm - genetics; Enzymes; Estrogens; Female; Gene expression; Gene regulation; Genetic aspects; Genomes; Genomics; Humans; Isoenzymes - genetics; Kaplan-Meier Estimate; Kinases; Messenger RNA; N-acetyltransferase 1; NAT1 gene; Normal distribution; Overall survival; Parameter identification; Parameter sensitivity; Patients; Populations; Proportional Hazards Models; Prostate; Prostate cancer; Receptors, Estrogen - metabolism; RNA, Messenger - genetics; RNA, Messenger - metabolism; Sensitivity; Survival; Taxonomy; Tumors
• ISSN: 1471-2164; 1471-2164
• DOI: 10.1186/s12864-018-4894-4

Arylamine N-acetyltransferase 1 (NAT1) is a drug metabolizing enzyme that has been associated with cancer cell proliferation in vitro and with survival in vivo. NAT1 expression has been associated with the estrogen receptor and it has been proposed as a prognostic marker for estrogen receptor positive cancers. However, little is known about the distribution of NAT1 mRNA across an entire patient population or its effects on outcomes. To address this, gene expression data from breast cancer patient cohorts were investigated to identify sub-populations based on the level of NAT1 expression. Patient survival and drug response was examined to determine whether NAT1 mRNA levels influenced any of these parameters. NAT1 expression showed a trimodal distribution in breast cancer samples (n = 1980) but not in tumor tissue from ovarian, prostate, cervical or colorectal cancers. In breast cancer, NAT1 mRNA in each sub-population correlated with a separate set of genes suggesting different mechanisms of NAT1 gene regulation. Kaplan-Meier plots showed significantly better survival in patients with highest NAT1 mRNA compared to those with intermediate or low expression. While NAT1 expression was elevated in estrogen receptor-positive patients, it did not appear to be dependent on estrogen receptor expression. Overall survival was analyzed in patients receiving no treatment, hormone therapy or chemotherapy. NAT1 expression correlated strongly with survival in the first 5 years in those patients receiving chemotherapy but did not influence survival in the other two groups. This suggests that low NAT1 expression is associated with chemo-resistance. The sensitivity of NAT1 mRNA levels as a single parameter to identify non-responders to chemotherapy was 0.58 at a log(2)